prod:prod_dcx-login
Xpert ® NPM1 Mutation
Fast, sensitive on-demand monitoring of NPM1 mutant mRNA transcripts in Acute Myeloid Leukemia patients
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXNPM1-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults.1 The Nucleophosmin (NPM1) mutation is one of the most common genetic abnormalities in AML, accounting for about 30% of cases.2,3
Established international organizations recommend periodic molecular assessment by quantitative PCR for monitoring NPM1 mutations in AML patients.4-6
No international scale is established for the quantification of the NPM1 mutant transcript for AML monitoring posing a challenge for quantitative monitoring.
Established international organizations recommend periodic molecular assessment by quantitative PCR for monitoring NPM1 mutations in AML patients.4-6
No international scale is established for the quantification of the NPM1 mutant transcript for AML monitoring posing a challenge for quantitative monitoring.
1 Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V,
Rigacci L. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy. Pharmgenomics Pers Med. 2022 Apr
22;15:393-407. doi: 10.2147/PGPM.S346688. PMID: 35496349; PMCID: PMC9041600.
2 Falini, B., Sciabolacci, S., Falini, L. et al. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia 35, 3113–3126 (2021). https://doi.org/10.1038/
s41375-021-01222-4. NCCN. Clinical Practice Guidelines in Oncology; Chronic Myelogenous Leukemia (Access Version 2.2024, December 2023).
3 Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R. When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018; 32(3): 167-183. doi:10.1016/j.blre.2017.11.001.
4 Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C. Acute myeloid leukemia in adult patients: ESMO Clinical Oractice Guidelines for
diagnosis, treatment and follow-up. Annals of Oncology, Special Article, Vol. 31, Issue 6, June 2020, Pages 697-712. doi: https://doi.org/10.1016/j.annonc.2020.02.018.
5 National Comprehensive Cancer Network. NCCN Guidelines for Patients – Acute Myeloid Leukemia, 2022. https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf.
Accessed on January 11, 2023.
6 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D,
Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations
from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
7 Xpert NPM1 Mutation Instructions for Use
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi: 10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
Rigacci L. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy. Pharmgenomics Pers Med. 2022 Apr
22;15:393-407. doi: 10.2147/PGPM.S346688. PMID: 35496349; PMCID: PMC9041600.
2 Falini, B., Sciabolacci, S., Falini, L. et al. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia 35, 3113–3126 (2021). https://doi.org/10.1038/
s41375-021-01222-4. NCCN. Clinical Practice Guidelines in Oncology; Chronic Myelogenous Leukemia (Access Version 2.2024, December 2023).
3 Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R. When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018; 32(3): 167-183. doi:10.1016/j.blre.2017.11.001.
4 Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C. Acute myeloid leukemia in adult patients: ESMO Clinical Oractice Guidelines for
diagnosis, treatment and follow-up. Annals of Oncology, Special Article, Vol. 31, Issue 6, June 2020, Pages 697-712. doi: https://doi.org/10.1016/j.annonc.2020.02.018.
5 National Comprehensive Cancer Network. NCCN Guidelines for Patients – Acute Myeloid Leukemia, 2022. https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf.
Accessed on January 11, 2023.
6 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D,
Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations
from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
7 Xpert NPM1 Mutation Instructions for Use
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi: 10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
The Solution
The Xpert NPM1 Mutation test is an automated test for quantifying the amount of mutant NPM1 mRNA transcripts (types A, B, and D in exon 12) as a ratio of NPM1 Mutation/ABL1.7
Proprietary in-house RNA control materials are used to calibrate and standardize each lot of the Xpert NPM1 Mutation.8
Proprietary in-house RNA control materials are used to calibrate and standardize each lot of the Xpert NPM1 Mutation.8
7 Xpert NPM1 Mutation Instructions for Use
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi: 10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi: 10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
The Impact
- Timely monitoring ensures measurement of treatment response and detection of potential relapse.6
- Quickly classify AML subtype (NPM1-mutant vs NPM1 wild type) to guide clinical decisions and prognosis.4
- Minimize challenges associated with result interpretation with a fast, easy-to-use, on-demand test and standardized reports.8
4 Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C. Acute myeloid leukemia in adult patients: ESMO Clinical Oractice Guidelines for
diagnosis, treatment and follow-up. Annals of Oncology, Special Article, Vol. 31, Issue 6, June 2020, Pages 697-712. doi: https://doi.org/10.1016/j.annonc.2020.02.018.
6 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D,
Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations
from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi:10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
diagnosis, treatment and follow-up. Annals of Oncology, Special Article, Vol. 31, Issue 6, June 2020, Pages 697-712. doi: https://doi.org/10.1016/j.annonc.2020.02.018.
6 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D,
Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations
from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
8 Liu Y, Kao M, Saatian B, Kayhan S, Zhao Y, Aslam A, Shridhar K, Yuan L. PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1
MUTATION PROTOTYPE ASSAY. Hemasphere. 2022 Jun 23;6(Suppl ):1655-1656. doi:10.1097/01.HS9.0000849952.50330.40. PMCID: PMC9429332.
Related Products
Xpert BCR-ABL Ultra
Delivering MORE confidence with fast, accurate Chronic Myeloid Leukemia molecular monitoring results
Xpert BCR-ABL Ultra p190
Sensitive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Monitoring